MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

8295	Companies
114858	Keywords
55302	Articles
62445	Press releases

Home
Companies
MIRA Pharmaceuticals

BRIEF

published on 07/22/2024 at 14:05, 3 months 29 days ago

MIRA Pharmaceuticals annonce des résultats précliniques prometteurs pour Ketamir-2

Troubles Neurologiques Résultats Précliniques Ketamir-2 Pénétration Cérébrale Demande FDA
BRIEF

published on 07/22/2024 at 14:05, 3 months 29 days ago

MIRA Pharmaceuticals Announces Promising Preclinical Results for Ketamir-2

Neurological Disorders Preclinical Results Ketamir-2 Brain Penetration FDA Application
PRESS RELEASE

published on 07/22/2024 at 14:00, 3 months 29 days ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
MIRA Pharmaceuticals reveals new promising preclinical data for Ketamir-2, a novel oral ketamine analog, indicating potential advantages for treating neurological and neuropsychiatric disorders

Preclinical Study Neurological Disorders MIRA Pharmaceuticals Neuropsychiatric Disorders Ketamir-2
BRIEF

published on 07/15/2024 at 13:05, 4 months 5 days ago

Mira Pharmaceuticals annonce des résultats prometteurs pour MIRA-55 dans plusieurs tests précliniques par rapport au THC

Médicaments Etudes Précliniques MIRA-55 Traitement De L'anxiété Comparaison Du THC
BRIEF

published on 07/15/2024 at 13:05, 4 months 5 days ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Pharmaceuticals Preclinical Studies MIRA-55 Anxiety Treatment THC Comparison
PRESS RELEASE

published on 07/15/2024 at 13:00, 4 months 5 days ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
MIRA Pharmaceuticals, Inc. confirms promising findings on new oral pharmaceutical marijuana analog, MIRA-55, as a potential treatment for neurological and neuropsychiatric disorders. Comparison to THC shows enhanced efficacy and consistent anxiolytic effects

Neurological Disorders Preclinical Studies MIRA-55 MIRA Pharmaceuticals Neuropsychiatric Disorders

Accesswire

Published on 11/21/2024 at 12:00, 28 minutes ago

Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 28 minutes ago

Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 58 minutes ago

FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 25 minutes ago

Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 28 minutes ago

BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:15, 12 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 21 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 27 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 57 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 1 hour 26 minutes ago

Original-Research: SMT Scharf AG (von Montega AG): Kaufen

Les Echos

Published on 11/21/2024 at 06:58, 5 hours 30 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 30 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 30 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 20 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 7 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE